HC Wainwright Raises Price Target On Outlook Therapeutics After Wet AMD Trial Data
H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating. The Company…
48 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures purchased 237,500 shares of Wilhelmina.
Mid-Morning Market Update: Markets Down; Alibaba Posts Downbeat Q1 Sales
Following the market opening Tuesday, the Dow traded down 0.20% to 34,767.20 while the NASDAQ fell 0.58% to 14,596.07. The S&P also fell, dropping 0.26% to 4,375.68.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Outlook Therapeutics Stock Surges Positive ONS-5010 Data In Wet AMD Patients
Outlook Therapeutics Inc (NASDAQ:OTLK) stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE…
Outlook Therapeutics Files For U.S. Patent Titled ‘BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=5344&p=107&f=G&l=50&d=PG01&S1=20210729.PD.&OS=PD/20210729&RS=PD/20210729